FierceBiotech ١٥ أبريل ٢٠٢٦ FDA official confirms plausible mechanism principles not exclusive to bespoke gene therapies
FierceBiotech ١٤ أبريل ٢٠٢٦ Australia’s Kazia pays research institute $1.4M for epigenetic platform, preclinical drug
FierceBiotech ١٤ أبريل ٢٠٢٦ Novo taps OpenAI to deploy AI across R&D, manufacturing and corporate functions
FierceBiotech ١٤ أبريل ٢٠٢٦ Cell therapy biotech Obsidian leverages Galera reverse merger to go public
FierceBiotech ١٤ أبريل ٢٠٢٦ Harbinger Health raises $100M for new suite of blood-based cancer detection tests
FierceBiotech ١٤ أبريل ٢٠٢٦ Alamar Biosciences files for IPO amid opening life sciences funding window
FierceBiotech ١٤ أبريل ٢٠٢٦ Boehringer, Amgen discard early immunology candidates over lack of clinical potential
FierceBiotech ١٣ أبريل ٢٠٢٦ Kailera outlines plans for $528.5M IPO to support quartet of Chinese obesity assets
FierceBiotech ١٣ أبريل ٢٠٢٦ Revolution’s much-hyped RAS inhibitor hits key survival goals in phase 3 pancreatic cancer trial
FierceBiotech ١٣ أبريل ٢٠٢٦ AbbVie inks $745M deal with Chinese biotech Haisco for two acute pain assets
FierceBiotech ١٣ أبريل ٢٠٢٦ Spyre points to phase 2 win for ulcerative colitis drug as proof it could take on Takeda’s Entyvio
FierceBiotech ١٣ أبريل ٢٠٢٦ BioNTech, SynOx plot paths to FDA as trials hit goals in competitive tumor types
FierceBiotech ١٣ أبريل ٢٠٢٦ Ideaya sees clear path to FDA as Servier-partnered eye cancer drug hits goal in phase 2/3 trial
FierceBiotech ١٣ أبريل ٢٠٢٦ Seaport, Hemab prepare for IPO voyages to fund depression, clotting candidates